Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP Ependymoma II
NL-OMON54695Phase 3Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, etoposide, vincristine, methotrexate and valproic acid in ependymoma (6 arms), sponsored by Centre Léon Bérard. Primary endpoints: Gross total resection rate, Progression-free survival and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
cisplatinetoposidevincristinemethotrexatevalproic acid
03
Conditions
ependymoma
Beyond the preview
Go deeper on NL-OMON54695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54695.